Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ

Jin Seok Kang, Seyl Kim, Jeong Hwan Che, KiTaek Nam, Dae Joong Kim, Dong Deuk Jang, Ki Hwa Yang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Epidemiological evidence indicates that estrogens are one of the risk factors of breast cancer. However, there have been reports that pre-pubertal estrogen exposure is related to reduced breast cancer risk. These discrepancies made us investigate the time-point and duration of estrogen exposure. Our studies focus on the effect of estradiol-3-benzoate (EB) on the mammary gland that was exposed to carcinogens. Ninety-six female Sprague-Dawley rats were randomly divided into 6 groups. Animals at 7 weeks of age were injected with 7,12-dimethylbenz[a]anthracene (DMBA) in groups 1, 2 and 3 or N-methyl-N-nitrosourea (MNU) in groups 4, 5 and 6. One week later, the animals were subjected to sustained treatment with 0 μg (groups 1 and 4), 30 μg (groups 2 and 5) or 300 μg (groups 3 and 6) of EB containing pellets for 4 weeks. All animals were sacrificed at 5 weeks or 21 weeks after carcinogen treatment, for the examination of mammary gland differentiation or mammary gland tumors, respectively. At 21 weeks after carcinogen treatment, the incidence of mammary tumors in group 2 was significantly decreased (P<0.05). EB treatment decreased the multiplicity of DMBA- or MNU-induced mammary gland tumors. At 5 weeks after carcinogen treatment, there were increased branchings of the mammary gland, and there was also a decrease of ERa and ERB in EB treatment groups. Taken together with these results, we conclude that EB has an inhibitory effect on mammary carcinogenesis, and it suggests that this inhibition may be associated with the differentiation of mammary gland and modulation of ERα and ERβ.

Original languageEnglish
Pages (from-to)689-693
Number of pages5
JournalOncology Reports
Volume12
Issue number4
Publication statusPublished - 2004 Oct 1

Fingerprint

Human Mammary Glands
Estrogen Receptors
Down-Regulation
Breast Neoplasms
Carcinogens
Methylnitrosourea
9,10-Dimethyl-1,2-benzanthracene
Estrogens
Sprague Dawley Rats
estradiol 3-benzoate
Carcinogenesis
Breast
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kang, Jin Seok ; Kim, Seyl ; Che, Jeong Hwan ; Nam, KiTaek ; Kim, Dae Joong ; Jang, Dong Deuk ; Yang, Ki Hwa. / Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ. In: Oncology Reports. 2004 ; Vol. 12, No. 4. pp. 689-693.
@article{04f737e3310e43b8aa5e4e1f4b366143,
title = "Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ",
abstract = "Epidemiological evidence indicates that estrogens are one of the risk factors of breast cancer. However, there have been reports that pre-pubertal estrogen exposure is related to reduced breast cancer risk. These discrepancies made us investigate the time-point and duration of estrogen exposure. Our studies focus on the effect of estradiol-3-benzoate (EB) on the mammary gland that was exposed to carcinogens. Ninety-six female Sprague-Dawley rats were randomly divided into 6 groups. Animals at 7 weeks of age were injected with 7,12-dimethylbenz[a]anthracene (DMBA) in groups 1, 2 and 3 or N-methyl-N-nitrosourea (MNU) in groups 4, 5 and 6. One week later, the animals were subjected to sustained treatment with 0 μg (groups 1 and 4), 30 μg (groups 2 and 5) or 300 μg (groups 3 and 6) of EB containing pellets for 4 weeks. All animals were sacrificed at 5 weeks or 21 weeks after carcinogen treatment, for the examination of mammary gland differentiation or mammary gland tumors, respectively. At 21 weeks after carcinogen treatment, the incidence of mammary tumors in group 2 was significantly decreased (P<0.05). EB treatment decreased the multiplicity of DMBA- or MNU-induced mammary gland tumors. At 5 weeks after carcinogen treatment, there were increased branchings of the mammary gland, and there was also a decrease of ERa and ERB in EB treatment groups. Taken together with these results, we conclude that EB has an inhibitory effect on mammary carcinogenesis, and it suggests that this inhibition may be associated with the differentiation of mammary gland and modulation of ERα and ERβ.",
author = "Kang, {Jin Seok} and Seyl Kim and Che, {Jeong Hwan} and KiTaek Nam and Kim, {Dae Joong} and Jang, {Dong Deuk} and Yang, {Ki Hwa}",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "12",
pages = "689--693",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ. / Kang, Jin Seok; Kim, Seyl; Che, Jeong Hwan; Nam, KiTaek; Kim, Dae Joong; Jang, Dong Deuk; Yang, Ki Hwa.

In: Oncology Reports, Vol. 12, No. 4, 01.10.2004, p. 689-693.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of mammary gland tumors by short-term treatment of estradiol-3-benzoate associated with down-regulation of estrogen receptor ERα and ERβ

AU - Kang, Jin Seok

AU - Kim, Seyl

AU - Che, Jeong Hwan

AU - Nam, KiTaek

AU - Kim, Dae Joong

AU - Jang, Dong Deuk

AU - Yang, Ki Hwa

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Epidemiological evidence indicates that estrogens are one of the risk factors of breast cancer. However, there have been reports that pre-pubertal estrogen exposure is related to reduced breast cancer risk. These discrepancies made us investigate the time-point and duration of estrogen exposure. Our studies focus on the effect of estradiol-3-benzoate (EB) on the mammary gland that was exposed to carcinogens. Ninety-six female Sprague-Dawley rats were randomly divided into 6 groups. Animals at 7 weeks of age were injected with 7,12-dimethylbenz[a]anthracene (DMBA) in groups 1, 2 and 3 or N-methyl-N-nitrosourea (MNU) in groups 4, 5 and 6. One week later, the animals were subjected to sustained treatment with 0 μg (groups 1 and 4), 30 μg (groups 2 and 5) or 300 μg (groups 3 and 6) of EB containing pellets for 4 weeks. All animals were sacrificed at 5 weeks or 21 weeks after carcinogen treatment, for the examination of mammary gland differentiation or mammary gland tumors, respectively. At 21 weeks after carcinogen treatment, the incidence of mammary tumors in group 2 was significantly decreased (P<0.05). EB treatment decreased the multiplicity of DMBA- or MNU-induced mammary gland tumors. At 5 weeks after carcinogen treatment, there were increased branchings of the mammary gland, and there was also a decrease of ERa and ERB in EB treatment groups. Taken together with these results, we conclude that EB has an inhibitory effect on mammary carcinogenesis, and it suggests that this inhibition may be associated with the differentiation of mammary gland and modulation of ERα and ERβ.

AB - Epidemiological evidence indicates that estrogens are one of the risk factors of breast cancer. However, there have been reports that pre-pubertal estrogen exposure is related to reduced breast cancer risk. These discrepancies made us investigate the time-point and duration of estrogen exposure. Our studies focus on the effect of estradiol-3-benzoate (EB) on the mammary gland that was exposed to carcinogens. Ninety-six female Sprague-Dawley rats were randomly divided into 6 groups. Animals at 7 weeks of age were injected with 7,12-dimethylbenz[a]anthracene (DMBA) in groups 1, 2 and 3 or N-methyl-N-nitrosourea (MNU) in groups 4, 5 and 6. One week later, the animals were subjected to sustained treatment with 0 μg (groups 1 and 4), 30 μg (groups 2 and 5) or 300 μg (groups 3 and 6) of EB containing pellets for 4 weeks. All animals were sacrificed at 5 weeks or 21 weeks after carcinogen treatment, for the examination of mammary gland differentiation or mammary gland tumors, respectively. At 21 weeks after carcinogen treatment, the incidence of mammary tumors in group 2 was significantly decreased (P<0.05). EB treatment decreased the multiplicity of DMBA- or MNU-induced mammary gland tumors. At 5 weeks after carcinogen treatment, there were increased branchings of the mammary gland, and there was also a decrease of ERa and ERB in EB treatment groups. Taken together with these results, we conclude that EB has an inhibitory effect on mammary carcinogenesis, and it suggests that this inhibition may be associated with the differentiation of mammary gland and modulation of ERα and ERβ.

UR - http://www.scopus.com/inward/record.url?scp=16644374773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644374773&partnerID=8YFLogxK

M3 - Article

C2 - 15375486

AN - SCOPUS:16644374773

VL - 12

SP - 689

EP - 693

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -